Solid Biosciences Inc

詳細情報 Solid Biosciences Inc 企業名

Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. The Company also has two cardiac pipeline gene transfer programs, SGT-601 for TNNT2 DCM and SGT-701 for RBM20 DCM, that are both in early preclinical development. It also has a neuromuscular gene transfer program for the treatment of Friedreich's ataxia. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.

企業情報

企業コードSLDB

会社名Solid Biosciences Inc

上場日Jan 26, 2018

最高経営責任者「CEO」Mr. Alexander (Bo) Cumbo

従業員数100

証券種類Ordinary Share

決算期末Jan 26

本社所在地500 Rutherford Avenue

都市CHARLESTOWN

証券取引所NASDAQ Global Select Consolidated

国United States of America

郵便番号02129

電話番号16173374680

ウェブサイトhttps://www.solidbio.com/

企業コードSLDB

上場日Jan 26, 2018

最高経営責任者「CEO」Mr. Alexander (Bo) Cumbo

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Ilan Ganot

Co-Founder, Director

132.92K

--

Mr. Ian F. Smith, CPA

Executive Chairman of the Board

122.12K

+3.89%

Mr. Alexander (Bo) Cumbo

President, Chief Executive Officer, Director

60.72K

--

Mr. David Tyronne (Ty) Howton, Jr.

Chief Operating Officer, General Counsel, secretary

24.79K

--

Mr. Kevin Tan

Chief Financial Officer, Treasurer

23.95K

+45.26%

Dr. Jessie Hanrahan, Ph.D.

Chief Regulatory Officer

19.28K

+35.45%

Mr. Paul Herzich

Chief Technology Officer

13.23K

+51.52%

Dr. Sukumar Nagendran, M.D.

Independent Director

4.15K

--

Dr. Martin I. Freed, M.D.

Independent Director

3.58K

--

Dr. Clare Kahn, Ph.D.

Independent Director

2.96K

+169.09%

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Ilan Ganot

Co-Founder, Director

132.92K

--

Mr. Ian F. Smith, CPA

Executive Chairman of the Board

122.12K

+3.89%

Mr. Alexander (Bo) Cumbo

President, Chief Executive Officer, Director

60.72K

--

Mr. David Tyronne (Ty) Howton, Jr.

Chief Operating Officer, General Counsel, secretary

24.79K

--

Mr. Kevin Tan

Chief Financial Officer, Treasurer

23.95K

+45.26%

Dr. Jessie Hanrahan, Ph.D.

Chief Regulatory Officer

19.28K

+35.45%

収益内訳

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

データなし

地域別USD

会社名

収益

比率

United States

0.00

0.00%

事業別

地域別

データなし

株主

更新時刻: Sat, Aug 16

株主統計

種類

株主統計

比率

Perceptive Advisors LLC

15.29%

Bain Capital Life Sciences Investors, LLC

10.16%

Invus Public Equities Advisors, LLC

9.52%

Adage Capital Management, L.P.

8.64%

RA Capital Management, LP

7.46%

他の

48.92%

株主統計

比率

Perceptive Advisors LLC

15.29%

Bain Capital Life Sciences Investors, LLC

10.16%

Invus Public Equities Advisors, LLC

9.52%

Adage Capital Management, L.P.

8.64%

RA Capital Management, LP

7.46%

他の

48.92%

種類

株主統計

比率

Investment Advisor

38.52%

Hedge Fund

26.93%

Investment Advisor/Hedge Fund

15.50%

Private Equity

15.29%

Venture Capital

7.46%

Research Firm

2.08%

Individual Investor

0.56%

Bank and Trust

0.13%

Insurance Company

0.03%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

237

81.08M

104.59%

+27.37M

2025Q1

237

79.86M

103.02%

+25.88M

2024Q4

198

36.85M

67.00%

-4.80M

2024Q3

199

36.30M

93.97%

-4.52M

2024Q2

188

37.99M

98.93%

-1.65M

2024Q1

182

35.35M

93.37%

+4.46M

2023Q4

181

16.93M

83.83%

-1.01M

2023Q3

190

16.39M

81.73%

-2.06M

2023Q2

203

16.54M

84.41%

-1.08M

2023Q1

234

16.00M

82.14%

-1.37M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Perceptive Advisors LLC

11.91M

15.36%

--

Mar 31, 2025

Bain Capital Life Sciences Investors, LLC

7.91M

10.21%

+2.88M

+57.15%

Mar 31, 2025

Invus Public Equities Advisors, LLC

7.42M

9.57%

+3.67M

+97.81%

Mar 31, 2025

Adage Capital Management, L.P.

6.73M

8.68%

+4.98M

+284.96%

Mar 31, 2025

RA Capital Management, LP

4.33M

5.59%

+90.74K

+2.14%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

1.92M

2.47%

+202.69K

+11.83%

Mar 31, 2025

The Vanguard Group, Inc.

2.46M

3.17%

+1.06M

+75.59%

Mar 31, 2025

Fidelity Management & Research Company LLC

3.52M

4.54%

+3.47M

+7432.14%

Mar 31, 2025

Citadel Advisors LLC

1.89M

2.43%

+937.47K

+98.85%

Mar 31, 2025

Monashee Investment Management, LLC

1.67M

2.16%

+1.19M

+248.63%

Mar 31, 2025

詳細を見る

5.440USD

Solid Biosciences Inc

5.440

概要

企業名

金融

分析